All In Biotech

Drug Trial Radar · NCT07667829

Vasopressor Agents in Pulmonary Hypertension Crisis

Comparison of the Efficacy and Safety of Dopamine, Norepinephrine and Epinephrine in the Treatment of Pulmonary Hypertensive Crisis Under Hemodynamic Monitoring

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Aug 19, 2026

Primary completion

Dec 31, 2028

Study completion Jan 31, 2029

Sponsor

Lead sponsor
China National Center for Cardiovascular DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring

Conditions

  • Pulmonary Arterial Hypertension (PAH)
  • Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
  • Hypertension, Pulmonary

Interventions

  • NorepinephrineDrug

    The initial dose is 0.02 mg/kg/min of norepinephrine; each dose adjustment (increase or decrease) is 0.02 mg/kg/min of norepinephrine; the maximum dose of norepinephrine is 0.2 mg/kg/min.

  • DopamineDrug

    The initial dose is 2 μg/kg/min of dopamine; each dose adjustment (increase or decrease) is 2 μg/kg/min of dopamine; the maximum dose of dopamine is 20 μg/kg/min

  • EpinephrineDrug

    The initial dose is 0.02 μg/kg/min of epinephrine; each adjustment (up or down) is 0.02 μg/kg/min of epinephrine; the maximum dose of epinephrine is 0.2 μg/kg/min

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortality within 28 daysTime frame: 28 days after enrolment

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Wuhan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.